Study of SGR-1505 in Mature B-Cell Neoplasms

Inclusion Criteria:

• Subject must have a history of histologically or cytologically confirmed matureB-cell malignancy.

• Subject must have measurable or detectable disease according to the applicabledisease-specific classification system and meet criteria for initiation oftreatment.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Life expectancy ≥ 12 weeks.

Exclusion Criteria:

• The subject is in need of immediate cytoreductive therapy (unless the patient has noremaining treatment choice with potential benefit).

• Subject has previous invasive malignancy in the last 2 years.

• Subject has a known allergy to SGR-1505 or excipients of SGR-1505.

• Subject has symptomatic or active CNS involvement of disease.

• Any other diseases, metabolic dysfunction, physical examination finding, or clinicallaboratory finding that would place the participant at increased risk to the use ofan investigational drug.